• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

iScience . Integrative Metabolomic and Proteomic Signatures Define Clinical Outcomes in Severe COVID-19

tetano

Editor, Senior Moderator
iScience


. 2022 Jun 17;104612.
doi: 10.1016/j.isci.2022.104612. Online ahead of print.
Integrative Metabolomic and Proteomic Signatures Define Clinical Outcomes in Severe COVID-19


Mustafa Buyukozkan[SUP] 1 2 [/SUP], Sergio Alvarez-Mulett[SUP] 3 [/SUP], Alexandra C Racanelli[SUP] 3 [/SUP], Frank Schmidt[SUP] 4 [/SUP], Richa Batra[SUP] 1 2 [/SUP], Katherine L Hoffman[SUP] 5 [/SUP], Hina Sarwath[SUP] 4 [/SUP], Rudolf Engelke[SUP] 4 [/SUP], Luis Gomez-Escobar[SUP] 3 [/SUP], Will Simmons[SUP] 5 [/SUP], Elisa Benedetti[SUP] 1 2 [/SUP], Kelsey Chetnik[SUP] 1 2 [/SUP], Guoan Zhang[SUP] 6 [/SUP], Edward Schenck[SUP] 3 [/SUP], Karsten Suhre[SUP] 7 [/SUP], Justin J Choi[SUP] 8 [/SUP], Zhen Zhao[SUP] 9 [/SUP], Sabrina Racine-Brzostek[SUP] 9 [/SUP], He S Yang[SUP] 9 [/SUP], Mary E Choi[SUP] 10 [/SUP], Augustine M K Choi[SUP] 3 [/SUP], Soo Jung Cho[SUP] 3 [/SUP], Jan Krumsiek[SUP] 1 2 [/SUP]



Affiliations

Abstract

The coronavirus disease-19 (COVID-19) pandemic has ravaged global healthcare with previously unseen levels of morbidity and mortality. In this study, we performed large-scale integrative multi-omics analyses of serum obtained from COVID-19 patients with the goal of uncovering novel pathogenic complexities of this disease and identifying molecular signatures that predict clinical outcomes. We assembled a network of protein-metabolite interactions through targeted metabolomic and proteomic profiling in 330 COVID-19 patients compared to 97 non-COVID, hospitalized controls. Our network identified distinct protein-metabolite cross talk related to immune modulation, energy and nucleotide metabolism, vascular homeostasis, and collagen catabolism. Additionally, our data linked multiple proteins and metabolites to clinical indices associated with long-term mortality and morbidity. Finally, we developed a novel composite outcome measure for COVID-19 disease severity based on metabolomics data. The model predicts severe disease with a concordance index of around 0.69, and shows high predictive power of 0.83-0.93 in two independent datasets.
 
Back
Top Bottom